2022
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals Of Hematology 2022, 101: 557-569. PMID: 34981142, PMCID: PMC9414073, DOI: 10.1007/s00277-021-04734-2.Peer-Reviewed Original ResearchConceptsAnti-drug antibodiesAcute myeloid leukemiaDose-limiting toxicityRefractory acute myeloid leukemiaHigh-risk myelodysplastic syndromeMyelodysplastic syndromeMyeloid leukemiaCommon treatment-emergent adverse eventsTreatment-emergent adverse eventsADA-positive patientsPhase 2 dosePresence/frequencyUnexpected safety findingsPhase 1 studyAnti-CD47 antibodyCD47-SIRPα interactionMacrophage-mediated killingHematological cancer cell linesFebrile neutropeniaMonotherapy activityCancer cell linesPrimary endpointSecondary endpointsAdverse eventsObjective response
2019
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Review Of Anticancer Therapy 2019, 19: 393-404. PMID: 30887841, PMCID: PMC6527485, DOI: 10.1080/14737140.2019.1589374.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalHumansImmunotherapyLeukemia, Myeloid, AcuteMyelodysplastic SyndromesTumor MicroenvironmentConceptsImmune checkpoint-based therapyImmune checkpoint inhibitorsAcute myeloid leukemiaMyelodysplastic syndromeNon-small cell lung cancerMultiple immune checkpoint inhibitorsTumor microenvironmentHematopoietic stem cell transplantAdvanced solid malignanciesStem cell transplantCell lung cancerInhibitory immune checkpointsImmunosuppressive tumor microenvironmentType of therapyMinimal residual diseaseInduction chemotherapyMonotherapy useRefractory settingCheckpoint inhibitorsImmune checkpointsTumor cell survivalCell transplantResidual diseaseSafety profileImmune system evasion
2018
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Reviews 2018, 34: 67-83. PMID: 30553527, DOI: 10.1016/j.blre.2018.12.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalBiomarkersCancer VaccinesClinical Trials as TopicHumansImmunotherapyImmunotherapy, AdoptiveLeukemia, Myeloid, AcuteMolecular Targeted TherapyMyelodysplastic SyndromesTreatment OutcomeConceptsHematopoietic stem cell transplantAcute myeloid leukemiaImmune checkpoint inhibitorsMyelodysplastic syndromeCheckpoint inhibitorsCell-based therapiesMyeloid leukemiaAllogeneic hematopoietic stem cell transplantCytotoxic T-lymphocyte-associated protein 4T-lymphocyte-associated protein 4Cell death protein 1Cell-based vaccinesNK cell therapyApplication of immunotherapyDeath protein 1Stem cell transplantAntibody-targeted therapyChimeric antigen receptorAntibody-based therapiesGemtuzumab ozogamicinDendritic cellsCell transplantImmunotherapeutic drugsT cellsClinical development